3 results
Approved WMOWill not start
To improve overall survival of patients with a early-stage high grade uterine leiomyosarcoma.
Approved WMOCompleted
To assess the effect of two withdrawal strategies over two years in patients with stable remission for more than 8 months on combination therapy with infliximab and antimetabolites, and demonstrate that continued combination of infliximab and…
Approved WMORecruiting
To compare the efficacy of MRTX849 versus docetaxel in patients with NSCLC with KRAS G12C mutation and who have received prior treatment with a platinum-based regimen and immune checkpoint inhibitor therapy.